Poland's HTA agency flags a comparator gap in Tevimbra's nasopharyngeal cancer submission. https://www.mattheneus.com/editorial/aotmit-tevimbra-nasopharyngeal-carcinoma-comparator-gap-assessment-2026-09-25 #HTA #Pharma #RegulatoryAffairs

An NMA ranks clozapine, paliperidone and olanzapine highest for reducing aggression in schizophrenia. Evidence certainty remains low. #HTA #NMA #EvidenceSynthesis https://www.mattheneus.com/editorial/pubmed-antipsychotic-aggression-network-meta-analysis-low-certainty-2026-09-24

BCI robotic rehabilitation ranks first for post-stroke arm recovery, with clinical relevance still uncertain. #HTA #EvidenceSynthesis https://www.mattheneus.com/editorial/pubmed-stroke-bci-robot-rehabilitation-network-clinical-threshold-2026-09-25

WHO recommends international scheduling for three synthetic drugs and keeps coca leaf controlled. #HTA #RegulatoryAffairs https://www.mattheneus.com/editorial/who-ecdd-48-synthetic-opioid-cannabinoid-coca-scheduling-2026-09-24

Africa’s childhood vaccine evidence base contained just one budget-impact analysis, exposing a critical gap for decision-makers. https://www.mattheneus.com/editorial/africa-childhood-vaccine-economic-evidence-budget-impact-gap-2026-09-24 #HTA #HealthEconomics #EvidenceSynthesis

Rare-disease trials need a defensible statistical file before enrolment starts. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/fda-rise-rare-disease-trial-statistical-design-file-2026-09-29

How often does living evidence stay living? Forty-one percent of syntheses issued an update within two years. #HTA #EvidenceSynthesis #Pharma https://www.mattheneus.com/editorial/living-evidence-synthesis-update-status-protocol-2026-09-25

Tenecteplase may improve outcomes and lower costs versus alteplase after acute ischaemic stroke in Canada. #HTA #HealthEconomics #Pharma https://www.mattheneus.com/editorial/pubmed-tenecteplase-alteplase-act-trial-canada-cost-effectiveness-2026-09-24

WHO’s first target product profiles for novel male contraceptives set clear efficacy and development thresholds. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/who-novel-male-contraceptive-target-product-profiles-efficacy-thresholds-2026-09-22

Swedish survival projections rose when trial follow-up doubled, showing the sensitivity of HTA extrapolations. #HTA #HealthEconomics #EvidenceSynthesis https://www.mattheneus.com/editorial/pubmed-swedish-hta-oncology-survival-extrapolation-extended-follow-up-audit-2026-09-26

WHO has set evidence thresholds for five contraceptive options, clarifying the path from emerging evidence to global guidance. #HTA #EvidenceSynthesis #RegulatoryAffairs https://www.mattheneus.com/editorial/who-expanding-contraceptive-options-five-evidence-thresholds-2026-09-23

Glaucoma evidence has a publication gap: four in ten conference abstracts reached full publication within six years. #HTA #EvidenceSynthesis https://www.mattheneus.com/editorial/glaucoma-conference-abstract-full-publication-selective-dissemination-evidence-synthesis-2026-09-25

Germany opens written comments on cardiac MRI for coronary heart disease, creating a timely opportunity to shape the evidence discussion. #HTA #RegulatoryAffairs https://www.mattheneus.com/editorial/germany-cardiac-magnetic-resonance-imaging-coronary-heart-disease-comment-procedure-2026-09-24

Hospital ward surveillance technologies still lack a clear effectiveness ranking in this Bayesian network meta-analysis. #HTA #NMA #EvidenceSynthesis https://www.mattheneus.com/editorial/pubmed-clinical-surveillance-technologies-non-icu-bayesian-network-meta-analysis-2026-09-24

Value-based price shifts with population eligibility: GBP 4,410 at list price, GBP 612 for the top tenth. https://www.mattheneus.com/editorial/cost-effectiveness-demand-curve-value-based-price-population-eligibility-2026-09-25 #HTA #HealthEconomics

A costed menu for global evidence synthesis infrastructure puts 40 solutions at US$278.3 million. https://www.mattheneus.com/editorial/evidence-synthesis-infrastructure-costed-menu-data-duplication-investment-2026-09-21 #HTA #EvidenceSynthesis #HealthEconomics

Six ways to record ethnicity, 21 ways to group it: subgroup comparisons stop meaning the same thing across studies. https://www.mattheneus.com/editorial/race-ethnicity-ascertainment-categorisation-clinical-research-subgroup-comparability-2026-09-21 #HTA #EvidenceSynthesis

G-BA resumes three stem cell transplantation assessments in multiple myeloma. https://www.mattheneus.com/editorial/g-ba-stem-cell-transplantation-multiple-myeloma-assessment-resumption-2026-09-24 #HTA #EvidenceSynthesis #Pharma

MHRA opens a call for evidence on AI for medicines safety, reaching beyond ADMET into validation and governance. https://www.mattheneus.com/editorial/mhra-beyond-admet-ai-medicines-safety-call-for-evidence-2026-09-22 #HTA #RegulatoryAffairs #RWE

Capacity-based exclusions in trial protocols quietly narrow the population HTA bodies must later generalise to. https://www.mattheneus.com/editorial/clinical-trial-protocol-capacity-exclusions-population-relevance-2026-09-25 #HTA #EvidenceSynthesis #RegulatoryAffairs